Advertisement
Singapore markets close in 1 hour 56 minutes

  • Straits Times Index

    3,364.74
    +26.17 (+0.78%)
     

  • Nikkei

    40,074.69
    +443.63 (+1.12%)
     

  • Hang Seng

    17,745.01
    +26.40 (+0.15%)
     

  • FTSE 100

    8,166.76
    +2.64 (+0.03%)
     

  • Bitcoin USD

    62,746.21
    -591.54 (-0.93%)
     

  • CMC Crypto 200

    1,347.81
    +3.31 (+0.25%)
     

  • S&P 500

    5,475.09
    +14.61 (+0.27%)
     

  • Dow

    39,169.52
    +50.66 (+0.13%)
     

  • Nasdaq

    17,879.30
    +146.70 (+0.83%)
     

  • Gold

    2,339.40
    +0.50 (+0.02%)
     

  • Crude Oil

    83.52
    +0.14 (+0.17%)
     

  • 10-Yr Bond

    4.4790
    +0.1360 (+3.13%)
     

  • FTSE Bursa Malaysia

    1,600.24
    +2.04 (+0.13%)
     

  • Jakarta Composite Index

    7,148.15
    +8.52 (+0.12%)
     

  • PSE Index

    6,352.30
    -46.47 (-0.73%)
     

Novo Nordisk ends kidney disease trial, books $816 million impairment in Q2

Reuters
·1-min read
FILE PHOTO: Novo Nordisk hopes to launch experimental obesity drug this decade

COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.

Novo has decided to stop its CLARION-CKD trial because it did not meet its primary endpoint of change in systolic blood pressure from baseline to week 12, the company said in a statement.

The impairment is related to ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, that Novo acquired from KBP Biosciences in October 2023, the Danish pharma giant said.

($1 = 6.9791 Danish crowns)

(Reporting by Louise Breusch Rasmussen, editing by Essi Lehto)